Diclofenac 25 mg 30 Tablets
active substance: diclofenac; 1 tablet contains diclofenac sodium 25 mg; auxiliary substances: lactose monohydrate, microcrystalline cellulose, corn starch, anhydrous colloidal silicon dioxide, talc, magnesium stearate; copolymer methacrylate dispersion, propylene glycol, talc, titanium dioxide (E 171), carmoisin (E 122).
Inflammatory and degenerative forms of rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spondyloarthritis);
pain syndromes from the spine;
acute attacks of gout;
post-traumatic and postoperative pain syndrome, accompanied by inflammation and edema, for example, after dental and orthopedic interventions; gynecological diseases accompanied by pain and inflammation, such as primary dysmenorrhea or adnexitis;
as an adjuvant in severe inflammatory diseases of the upper respiratory tract, accompanied by a feeling of pain, for example, with pharyngotonsillitis, otitis media.
According to general therapeutic principles, the underlying disease should be treated with basic therapy. Fever itself is not an indication for the use of the drug.
Hypersensitivity to the active substance or to any other components of the drug. Diclofenac-Darnitsa, like other non-steroidal anti-inflammatory drugs (NSAIDs), is contraindicated in patients who, in response to the use of acetylsalicylic acid or other NSAIDs, develop asthma attacks, urticaria or acute rhinitis, nasal polyps and other allergic symptoms. The last trimester of pregnancy. Acute stomach or intestinal ulcer; gastrointestinal bleeding or perforation. Inflammatory bowel disease (Crohn’s disease or ulcerative colitis). Severe liver failure (Child-Pugh class C, cirrhosis or ascites). Severe renal impairment (creatinine clearance <30 ml / min). Congestive heart failure (YUNA H-1U). Ischemic heart disease in patients with angina pectoris, myocardial infarction. Cerebrovascular diseases in patients who have suffered a stroke or have episodes of transient ischemic attacks. Peripheral artery disease. Treatment of postoperative pain after coronary artery bypass grafting (or heart-lung machine).
The dosage regimen is set individually, taking into account the indications and the severity of the condition. Diclofenac-Darnitsa should be taken orally, the tablets should be swallowed without chewing, after meals, with a sufficient amount of water. The drug should be used in the lowest effective doses for the shortest period of time, taking into account the goals of treatment for each patient separately. Adults. The starting dose is usually 100-150 mg per day. With unexpressed symptoms, as well as with prolonged therapy, a dose of 75-100 mg / day is sufficient. The daily dose is divided into 2-3 doses. To avoid night pain or morning stiffness, treatment with Diclofenac-Darnitsa can be supplemented by prescribing rectal suppositories containing diclofenac before bedtime. The daily dose should not exceed 150 mg. In primary dysmenorrhea, the daily dose should be selected individually, usually it is 50-150 mg. The initial dose can be 50-100 mg, but if necessary, it can be increased over several menstrual cycles to a maximum of 200 mg per day. The use of the drug should be started after the onset of the first painful symptoms and continued for several days, depending on the dynamics of regression of symptoms. Children. Tablets at a dose of 25 mg can be used by children from 8 years old (weighing at least 25 kg) to 14 years old as prescribed by a doctor at a dose of 0.5-2 mg / kg body weight, depending on the severity of symptoms: this dose is divided by 2 3 receptions. For example, for a child weighing 30 kg, the daily dose may be 15 to 60 mg. Based on this range, the child can be prescribed 2 tablets of 25 mg 2 times a day. In the treatment of juvenile rheumatoid arthritis, the daily dose can be increased to 3 mg / kg – the maximum daily dose. The maximum daily dose of 150 mg should not be exceeded. For children from 14 years old, use 75 to 150 mg per day in 2-3 doses. The daily dose should not exceed 150 mg.
Keep out of the reach of children in the original packaging at a temperature not exceeding 25 ° C.